|
|
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1280-1283.
Prepublished online as a Blood First Edition Paper on May 9, 2006; DOI 10.1182/blood-2006-04-015701.
 Previous Article | Next Article 
Submitted April 7, 2006
Accepted April 10, 2006
The thrombospondin-1 N700S polymorphism is associated with
early myocardial infarction without altering von
Willebrand Factor multimer size
Jeffrey I Zwicker*, Flora Pevandi, Roberta Palla, Rossana Lombardi, Maria Teresa Canciani, Andrea Cairo, Diego Ardissino, Luisa Bernardinelli, Kenneth A Bauer, Jack Lawler, and P.M. Mannucci
Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
A. Bianchi Bonomi Hemophilia and Thrombois Center, University of Milan
Maggiore Hospital, University of Parma
Medical Research Council Biostatistics Unit, Cambridge (UK)
Beth Israel Deaconess Medical Center
* Corresponding author; email: jzwicker{at}bidmc.harvard.edu.
The N700S polymorphism of thrombospondin-1 (TSP-1) has
been identified as a potential genetic risk factor for
myocardial infarction (MI). In a large case-control
study of 1425 individuals who survived a myocardial
infarction prior to age 45, the N700S polymorphism was a
significant risk factor for myocardial infarction in
both homozygous (OR 1.9, 95% CI 1.1-3.3, P=0.01) and
heterozygous carriers of the S700 allele (OR 1.4, 95% CI
1.1-3.3, P=0.01) . TSP-1 has been shown to reduce von
Willebrand Factor (VWF) multimer size and the domain
responsible for VWF-reducing activity has been localized
to the calcium-binding C-terminal sequence. As the N700S
polymorphism was previously shown to alter the function
of this domain, we investigated whether the altered VWF-
reducing activity of TSP-1 underlies the observed
prothrombotic phenotype. The TSP-1 N700S polymorphism
did not influence VWF multimer size in patients
homozygous for either allele nor was there a significant
reduction of VWF multimer size following incubation with
recombinant N700S fragments or platelet derived TSP-1
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y.-C. Liao, H.-F. Lin, T. Rundek, R. Cheng, Y.-C. Guo, R. L. Sacco, and S.-H. H. Juo
Segment-Specific Genetic Effects on Carotid Intima-Media Thickness: The Northern Manhattan Study
Stroke,
December 1, 2008;
39(12):
3159 - 3165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. B. Carlson, Y. Liu, J. L. Keck, and D. F. Mosher
Influences of the N700S Thrombospondin-1 Polymorphism on Protein Structure and Stability
J. Biol. Chem.,
July 18, 2008;
283(29):
20069 - 20076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Koch, P. Hoppmann, A. de Waha, A. Schomig, and A. Kastrati
Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence
Hum. Mol. Genet.,
April 15, 2008;
17(8):
1120 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Isenberg, M. J. Romeo, C. Yu, C. K. Yu, K. Nghiem, J. Monsale, M. E. Rick, D. A. Wink, W. A. Frazier, and D. D. Roberts
Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling
Blood,
January 15, 2008;
111(2):
613 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. I. Stenina, E. J. Topol, and E. F. Plow
Thrombospondins, Their Polymorphisms, and Cardiovascular Disease
Arterioscler Thromb Vasc Biol,
September 1, 2007;
27(9):
1886 - 1894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kaczorowski and T. R. Billiar
Targeting CD47: NO Limit on Therapeutic Potential
Circ. Res.,
March 16, 2007;
100(5):
602 - 603.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Raman, I. Krukovets, T. E. Marinic, P. Bornstein, and O. I. Stenina
Glycosylation Mediates Up-regulation of a Potent Antiangiogenic and Proatherogenic Protein, Thrombospondin-1, by Glucose in Vascular Smooth Muscle Cells
J. Biol. Chem.,
February 23, 2007;
282(8):
5704 - 5714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
